What: Freenome detects cancer using a multiomics platform that integrates molecular biology with advanced computational biology and machine learning. This approach analyses tumour and non-tumour signals from a routine blood draw, detecting cancer at its earliest stages. Freenome's flagship study, PREEMPT CRC, aims to validate their blood test for colorectal cancer (CRC) screening. With over 35,000 participants, this study seeks to demonstrate the test's sensitivity and specificity across diverse populations. Additionally, the Vallania Study expands this technology to multiple cancers, including lung and pancreatic cancers, striving to enhance early detection and optimize patient care pathways. ​

What: PathAI's AISight™ platform integrates with Laboratory Information Systems (LIS) to enhance pathology workflows. It ensures HIPAA-compliant data transmission of case details and whole slide images (WSI) from the lab to AISight™. The platform allows users to launch AISight™ directly from the LIS for both onsite and remote image analysis. It supports the deployment of AI algorithms, including AIM PD-L1 and AIM HER2, which assist in the detailed analysis of pathological samples. This integration aims to optimize diagnostic accuracy and efficiency in pathology labs.​

What: In 2022, Intelerad acquired PenRad Technologies to enhance their breast and lung cancer screening capabilities. PenRad's software, including PenRad for breast imaging and PenLung for lung cancer screening, integrates with Intelerad’s imaging platform. This combination optimizes radiologist workflows, improves diagnostic accuracy, and helps manage the increased demand for cancer screenings. This acquisition aims to provide efficient, scalable imaging solutions that support healthcare professionals in delivering better patient care and outcomes.​

What: Successfully commercialised in 2023 after 15 years of development and testing, the assessment algorithm takes 2D magnetic resonance (MR) images and converts them into the much more expensive (and thus less commonly ordered) 3D versions. By automating this process, the algorithm can increase the quality of scans, provide earlier detection of knee osteoarthritis, and save healthcare costs. The CSIRO algorithm has the additional benefit of creating images that can be more accurately analysed by diagnostic AI algorithms. By presenting the images in AI-readable forms, it further expands the possibilities for rapid AI-powered diagnoses at a time when the demand for radiologist reviews is outstripping supply.​

What: Intelligencia AI uses artificial intelligence to improve the probability of success in drug development. The platform leverages machine learning to assess the probability of technical and regulatory success (PTRS) of drug candidates, making use of vast and diverse datasets. By providing data-driven insights, Intelligencia helps pharmaceutical companies make informed decisions, prioritize promising candidates, and reduce development costs. Intelligencia AI's algorithm analyse patterns and interdependencies in extensive datasets, offering accurate PTRS predictions and enhancing decision-making at critical stages. ​

What: Healthily revolutionizes health insurance with its AI-powered virtual health assistant, Dot™. This platform uses smart symptom navigation to provide members with medically validated information, guiding them to the most appropriate next steps for their health concerns. Dot™ helps reduce unnecessary and inefficient pathways, improving patient outcomes while saving costs for insurers. By automating symptom assessment and signposting, Dot™ minimizes the burden on healthcare professionals and call centres, allowing for more efficient resource utilization. Since 2015, Healthily has ensured that safety and medical accuracy are paramount, enhancing the overall healthcare experience for users.​

What: Mass General Brigham’s Innovation Office is pioneering advancements in biotech diagnostics through strategic collaborations and cutting-edge research. Partnering with industry leaders like Roche Diagnostics, they facilitate the integration of advanced diagnostic tools into clinical practice. A notable example is Roche’s cobas® EGFR Mutation Test v2, which identifies mutations in non-small cell lung cancer (NSCLC) patients, enabling targeted and personalized treatment strategies. The Innovation Office at Mass General Brigham ensures these developments translate into real-world clinical applications, improving patient outcomes through precision medicine. By leveraging the cobas® EGFR Mutation Test v2, clinicians can make informed decisions about the most effective therapies, highlighting the critical role of advanced diagnostics in modern healthcare. This collaboration underscores Mass General Brigham’s commitment to enhancing diagnostic capabilities and delivering superior patient care through innovative biotech solutions.

What: Genomics England's landmark initiative, the 100,000 Genomes Project, involves sequencing genomes from 85,000 NHS patients affected by rare diseases or cancer. This project aims to integrate genomics into routine healthcare, create a global genomic data resource, and provide actionable insights for participants. Initial findings have already led to significant breakthroughs, including new diagnoses for 25% of early participants through whole genome sequencing (WGS). Notably, 14% of these diagnoses were in genomic regions missed by other testing methods. The project continues to yield valuable data for research, contributing to the development of new treatments and diagnostics. Participant consent governs data sharing with approved researchers, ensuring ethical use and ongoing benefits from this vast genomic dataset.

What: The Centre for Digital Health (CDH) at Stanford University actively invests in research and development to drive continuous improvement and innovation in healthcare delivery. Projects funded by CDH include the development of AI-based approaches to support adherence behaviours in psychiatric care, and virtual therapists for stroke recovery, demonstrating the integration of advanced technologies to enhance patient outcomes and streamline care processes. Innovative digital health clinical trials, such as those focusing on improving anticoagulation adherence and digital cardiac rehabilitation, exemplify the use of digital tools and mobile health applications to enhance clinical trial design and patient care. 

What: Catalent's Case Management Service utilizes advanced technology and comprehensive oversight to manage the complex supply chains of cell and gene therapies. Each therapy is assigned a dedicated Case Manager who oversees the entire process—from material collection to manufacturing, and finally, to delivery—ensuring chain of custody and identity are meticulously maintained. The service includes continuous status monitoring, proactive updates, and 24/7 support, reducing risks and ensuring timely administration of therapies. This system leverages Catalent’s global manufacturing and distribution network, enhancing efficiency and scalability for biotech companies.